- Home
- PFE
PFE
Pfizer Inc.
as 05-30-2025 4:00pm EST
| Founded: | 1849 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $29.92 | AVG Volume (30 days): | 45.6M |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.91 - $31.54 | Next Earning Date: | 04-29-2025 |
| Revenue: | $62,464,000,000 | Revenue Growth: | 11.65% |
| Revenue Growth (this year): | -1.03% | Revenue Growth (next year): | -0.28% |
Latest Pfizer Inc. News
PFE Breaking Stock News: Dive into PFE Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 hours ago
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
BioPharma Dive
18 hours ago
Full Arvinas, Pfizer data confirm potential and limits of ‘Protac’ drug in breast cancer
Benzinga
a day ago
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%
Pharmaceutical Technology
a day ago
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
MT Newswires
2 days ago
Pfizer Says Braftovi Combination Regimen Halved Death Risk in Colorectal Cancer Study
Business Wire
2 days ago
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Insider Monkey
2 days ago
Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes
Simply Wall St.
2 days ago
Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges
Compare PFE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PFE Pfizer Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.